SEATTLE and SOUTH SAN FRANCISCO, Calif., May 11, 2015 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced that Carlos Paya, M.D., Ph.D., President and Chief Executive Officer, will present at upcoming investor conferences in May and June.
|Bank of America Merrill Lynch 2015 Health Care Conference|
|Thursday, May 14, 2015 at 9:20 a.m. Pacific Time in Las Vegas.|
|UBS 2015 Global Healthcare Conference|
|Tuesday, May 19, 2015 at 2 p.m. Eastern Time in New York.|
|Jefferies 2015 Healthcare Conference|
|Wednesday, June 3, 2015 at 2 p.m. Eastern Time in New York.|
A live webcast of each presentation will be available online from the investor relations page of the company's corporate website at http://ir.immunedesign.com/events.cfm. After the live webcast, an archive of each presentation will be available on the company website.
About Immune Design
Immune Design is a clinical-stage immunotherapy company employing next-generation in vivo approaches to enable the body's immune system to fight disease. The company's technologies are engineered to activate the immune system's natural ability to generate and/or expand antigen-specific cytotoxic T cells, while enhancing other immune effectors, to fight cancer and other chronic diseases. CMB305 and G100, the two-pronged focus of Immune Design's ongoing immuno-oncology clinical programs, are the product of its two synergistic discovery platforms: ZVexTM and GLAASTM. Immune Design has offices in Seattle and South San Francisco. For more information, visit www.immunedesign.com.